DGIdb - MORPHINE Drug Record

MORPHINE chembl:CHEMBL70 Approved

Alternate Names:

IDS-NM-009
INFUMORPH
AVINZA
N02AA01
KADIAN
MORPHINE
DEPODUR
ANHYDROUS MORPHINE
(5Α,6Α)-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINAN-3,6-DIOL
(5Α,6Α)-17-METHYL-7,8-DIDEHYDRO-4,5-EPOXYMORPHINAN-3,6-DIOL
(5R,6S,9R,13S,14R)-4,5-EPOXY-N-METHYL-7-MORPHINEN-3,6-DIOL
MORPHINE SULFATE
ORAMORPH®
(5ALPHA,6ALPHA)-17-METHYL-7,8-DIDEHYDRO-4,5-EPOXYMORPHINAN-3,6-DIOL
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
MORPHINUM
MORPHIUM
MORPHIN
(-)-MORPHINE
(5ALPHA,6ALPHA)-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINAN-3,6-DIOL
MORFINA
MORPHIA
(−)-MORPHINE
MS CONTIN®
chembl:CHEMBL70
pubchem.compound:5288826
rxcui:7052
chemidplus:57-27-2
drugbank:00295

Drug Info:

Year of Approval	approved before 1982
Drug Class	analgesics, opioid
Drug Categories	phenanthrenes
Drug Class	Small molecule
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	analgesic
Drug Categories	anesthetics
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 substrates
Drug Categories	heterocyclic compounds, fused-ring
Drug Categories	high-risk opioids
Drug Categories	natural opium alkaloids
Drug Categories	neuraxial anesthetics
Drug Categories	opiate agonists
Drug Categories	opioid agonist
Drug Categories	opioids
Drug Categories	p-glycoprotein substrates
Drug Categories	serotonergic drugs shown to increase risk of serotonin syndrome
Drug Categories	ugt1a1 substrates
Drug Categories	ugt1a3 substrates
Drug Categories	ugt2b7 substrates

(5 More Sources)

Publications:

El-Hage et al., 2006, CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates., J. Neuroimmunol.
Koch et al., 2006, Role of phospholipase D2 in the agonist-induced and constitutive endocytosis of G-protein coupled receptors., J. Neurochem.
Galeotti et al., 2006, Signaling pathway of morphine induced acute thermal hyperalgesia in mice., Pain
Kieffer et al., 2002, Exploring the opioid system by gene knockout., Prog. Neurobiol.
Yamada et al., 2006, Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors., Brain Res.
Dortch-Carnes et al., 2006, Morphine-induced reduction of intraocular pressure and pupil diameter: role of nitric oxide., Pharmacology
Asensio et al., 2006, Stimulation of mitogen-activated protein kinase kinases (MEK1/2) by mu-, delta- and kappa-opioid receptor agonists in the rat brain: regulation by chronic morphine and opioid withdrawal., Eur. J. Pharmacol.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Robinson et al., 2002, Widespread but regionally specific effects of experimenter- versus self-administered morphine on dendritic spines in the nucleus accumbens, hippocampus, and neocortex of adult rats., Synapse
Teodorov et al., 2006, Preliminary study of the effects of morphine treatment on opioid receptor gene expression in brain structures of the female rat., Neuroscience
Chatti I et al., 2017, Genetic Analysis of Mu and Kappa Opioid Receptor and COMT Enzyme in Cancer Pain Tunisian Patients Under Opioid Treatment., Iran J Public Health
Kozak et al., 1994, Murine chromosomal location of the mu and kappa opioid receptor genes., Genomics
Leventhal et al., 1998, Morphine-6beta-glucuronide-induced hyperphagia: characterization of opioid action by selective antagonists and antisense mapping in rats., J. Pharmacol. Exp. Ther.
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Zhu XL et al., 2020, Correlations of analgesic dosage of morphine with SLC6A4 gene polymorphisms in patients with lung cancer., Eur Rev Med Pharmacol Sci
Bastami S et al., 2014, Influence of UGT2B7, OPRM1 and ABCB1 gene polymorphisms on postoperative morphine consumption., Basic Clin Pharmacol Toxicol
Sadhasivam S et al., 2015, Opioid-induced respiratory depression: ABCB1 transporter pharmacogenetics., Pharmacogenomics J
Cunningham CW et al., 2008, Opioids and efflux transporters. Part 2: P-glycoprotein substrate activity of 3- and 6-substituted morphine analogs., J Med Chem
Coulbault L et al., 2006, Environmental and genetic factors associated with morphine response in the postoperative period., Clin Pharmacol Ther
Aubrun F et al., 2018, Opioid-related genetic polymorphisms do not influence postoperative opioid requirement: A prospective observational study., Eur J Anaesthesiol
Venkatasubramanian R et al., 2014, ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children., Pharmacogenomics
Lötsch J et al., 2009, Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers., Pharmacogenet Genomics
Campa D et al., 2008, Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief., Clin Pharmacol Ther
Candiotti KA et al., 2009, The impact of CYP2D6 genetic polymorphisms on postoperative morphine consumption., Pain Med
Sindrup SH et al., 1993, Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?, Pain
Foster A et al., 2007, Complicated pain management in a CYP450 2D6 poor metabolizer., Pain Pract
Vaught et al., 1978, Characterization of leucine and methionine enkephalin and their interaction with morphine on the guinea pig ileal longitudinal muscle., Res. Commun. Chem. Pathol. Pharmacol.
Darbari DS et al., 2008, UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease., Am J Hematol
Matic M et al., 2014, Effect of UGT2B7 -900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results from a pilot cohort., Pharmacogenomics
Holthe M et al., 2002, Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy., Eur J Clin Pharmacol
Nielsen LM et al., 2017, Lack of genetic association between OCT1, ABCB1, and UGT2B7 variants and morphine pharmacokinetics., Eur J Pharm Sci
Ning M et al., 2019, Roles of UGT2B7 C802T gene polymorphism on the efficacy of morphine treatment on cancer pain among the Chinese han population., Niger J Clin Pract
Liang et al., 2003, Heme oxygenase type 2 modulates behavioral and molecular changes during chronic exposure to morphine., Neuroscience
Li et al., 2000, Chronic morphine exposure and the expression of heme oxygenase type 2., Brain Res. Mol. Brain Res.
Liu et al., 2005, [The effect of ribozyme specially cleaving per1 mRNA on c-fos mRNA and its expression in hippocampus of morphine addicted mice]., Space Med Med Eng (Beijing)
Sharif et al., 2002, Attenuation of morphine tolerance after antisense oligonucleotide knock-down of spinal mGluR1., Br. J. Pharmacol.
Xu et al., 1996, L-740,093, a new antagonist of the CCK-B receptor, potentiates the antinociceptive effect of morphine: electrophysiological and behavioural studies., Neuropeptides
Ipp et al., 1980, Morphine-induced hyperglycemia: role of insulin and glucagon., Endocrinology
Zhu et al., 2003, Region-specific changes in NMDA receptor mRNA induced by chronic morphine treatment are prevented by the co-administration of the competitive NMDA receptor antagonist LY274614., Brain Res. Mol. Brain Res.
Singhal et al., 2002, Role of p38 mitogen-activated protein kinase phosphorylation and Fas-Fas ligand interaction in morphine-induced macrophage apoptosis., J. Immunol.
Nikolaev VO et al., 2007, Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors., J Biol Chem
Choi et al., 2006, The opioid ligand binding of human mu-opioid receptor is modulated by novel splice variants of the receptor., Biochem. Biophys. Res. Commun.
Johnson et al., 2006, Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells., Mol. Pharmacol.
Vilardaga JP et al., 2008, Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling., Nat Chem Biol
Tidgewell K et al., 2008, Herkinorin analogues with differential beta-arrestin-2 interactions., J Med Chem
Castro et al., 2006, A quantitative approach to measure joint pain in experimental osteoarthritis--evidence of a role for nitric oxide., Osteoarthr. Cartil.
Somogyi AA et al., 2016, Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain., Pain
Rouge-Pont et al., 2002, Changes in extracellular dopamine induced by morphine and cocaine: crucial control by D2 receptors., J. Neurosci.
Menzebach et al., 2004, [Morphine inhibits complement receptor expression, phagocytosis and oxidative burst by a nitric oxide dependent mechanism]., Anasthesiol Intensivmed Notfallmed Schmerzther
Groer et al., 2007, An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization., Mol. Pharmacol.
Werme et al., 2000, NGFI-B and nor1 mRNAs are upregulated in brain reward pathways by drugs of abuse: different effects in Fischer and Lewis rats., Brain Res. Mol. Brain Res.
Hahn D et al., 2020, Influence of MRP3 Genetics and Hepatic Expression Ontogeny for Morphine Disposition in Neonatal and Pediatric Patients., J Clin Pharmacol
Parmar et al., 1987, Studies on the possible mechanism of morphine-induced potentiation of the gastroulcerogenic effect of indomethacin in rats., Arch Int Pharmacodyn Ther
Galvan A et al., 2011, Multiple Loci modulate opioid therapy response for cancer pain., Clin Cancer Res
Khrenov et al., 2000, [Quantitative analysis of synaptophysin (p38) in the brain of the second generation offspring from male rats with long-term morphine intoxication]., Biull Eksp Biol Med
Tzvetkov MV et al., 2013, Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration., Biochem Pharmacol
Elens L et al., 2016, Genetic Predisposition to Poor Opioid Response in Preterm Infants: Impact of KCNJ6 and COMT Polymorphisms on Pain Relief After Endotracheal Intubation., Ther Drug Monit
Horowitz R et al., 2000, Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study., Am J Med Genet
Zubieta JK et al., 2003, COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor., Science
Hronová K et al., 2016, Sufentanil and midazolam dosing and pharmacogenetic factors in pediatric analgosedation and withdrawal syndrome., Physiol Res
Rakvåg TT et al., 2005, The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients., Pain
De Gregori M et al., 2013, Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain., Eur J Clin Pharmacol
Klepstad P et al., 2011, Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients., Pain
Landau R et al., 2013, The effect of OPRM1 and COMT genotypes on the analgesic response to intravenous fentanyl labor analgesia., Anesth Analg
De Gregori M et al., 2016, Human Genetic Variability Contributes to Postoperative Morphine Consumption., J Pain
Cargnin S et al., 2013, An opposite-direction modulation of the COMT Val158Met polymorphism on the clinical response to intrathecal morphine and triptans., J Pain
Vandenbergh DJ et al., 1997, High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers., Am J Med Genet
Matic M et al., 2014, Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotype., Pharmacogenomics
Candiotti KA et al., 2014, Catechol-o-methyltransferase polymorphisms predict opioid consumption in postoperative pain., Anesth Analg
Matic M et al., 2017, Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement., Pharmacogenomics
Hutchinson MR et al., 2010, Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences., Neuroscience

MORPHINE SYP

Interaction Score: 3.55

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10710628

Sources:
NCI
MORPHINE PDYN

Interaction Score: 3.55

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
705020

Sources:
NCI
MORPHINE PER1

Interaction Score: 1.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15977398

Sources:
NCI
MORPHINE HMOX2

Interaction Score: 1.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14580950 10686338

Sources:
NCI
MORPHINE RHBDF2

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21622719

Sources:
PharmGKB
MORPHINE LPAR2

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17090705

Sources:
NCI
MORPHINE SULT1A4

Interaction Score: 0.89

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
MORPHINE TAOK3

Interaction Score: 0.89

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
MORPHINE COMT

Interaction Score: 0.79

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11054766 12595695 28006928 15927391 23686330 21398039 23302985 26902643 29474345 23773341 9259381 25155931 25185591 19514130 28745577 27027462

Sources:
PharmGKB
MORPHINE LY96

Interaction Score: 0.71

Interaction Types & Directionality:

activator (activating)

Interaction Info:

PMIDs:
20178837

Sources:
DrugBank
MORPHINE UGT2B7

Interaction Score: 0.68

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17724700 25340733 24703092 16580900 12185559 28063968 31607718

Sources:
PharmGKB
MORPHINE GRM1

Interaction Score: 0.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12110611

Sources:
NCI
MORPHINE KCNJ6

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27027462

Sources:
PharmGKB
MORPHINE NR4A1

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10719211

Sources:
NCI
MORPHINE ITGAM

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15098168

Sources:
NCI
MORPHINE CCR2

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16831471

Sources:
NCI
MORPHINE SLC22A1

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23835420

Sources:
PharmGKB
MORPHINE OPRD1

Interaction Score: 0.24

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

PMIDs:
16539674 16650582 12015197 16530171 16534251 16678156 11752352

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology
MORPHINE GCG

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6993188

Sources:
NCI
MORPHINE F2R

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12373743

Sources:
NCI
MORPHINE OPRK1

Interaction Score: 0.17

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name TPM-1/Morphine

Trial Name Statex

Trial Name MoxDuo

PMIDs:
16753266 29259946 7959748 9808678 17139284 17016423

Sources:
TEND PharmGKB TdgClinicalTrial DrugBank GuideToPharmacology
MORPHINE CCKBR

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8771563

Sources:
NCI
MORPHINE OPRM1

Interaction Score: 0.16

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

Novel drug target Established target

Trial Name intranasal morphine,Rylomine

PMIDs:
17616524 16580639 16682505 16530171 18193048 18380425 11752352 16580848

Sources:
TEND DTC TdgClinicalTrial DrugBank GuideToPharmacology
MORPHINE TBXA2R

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3435201

Sources:
NCI
MORPHINE ABCC3

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
32090339

Sources:
PharmGKB
MORPHINE IL1B

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27649267

Sources:
PharmGKB
MORPHINE ABCB1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24703092 25311385 18311899 16580900 29474345 25155932 19514130 17898703

Sources:
DTC PharmGKB
MORPHINE GRIN1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12829326

Sources:
NCI
MORPHINE SLC6A4

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
32432768

Sources:
PharmGKB
MORPHINE MAPK14

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11937560

Sources:
NCI
MORPHINE DRD2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11943831

Sources:
NCI
MORPHINE CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19523031 8351162 17986163

Sources:
PharmGKB

DrugBank: DB00295

Version: 5.1.7

Alternate Names:

57-27-2 CAS Number

Arymo ER Drug Brand

Astramorph Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Choi et al., 2006, The opioid ligand binding of human mu-opioid receptor is modulated by novel splice variants of the receptor., Biochem. Biophys. Res. Commun.

Johnson et al., 2006, Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells., Mol. Pharmacol.

Yamada et al., 2006, Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors., Brain Res.

TEND: MORPHINE
- Version: 01-August-2011
Alternate Names:

Drug Info:

Drug Class analgesics, opioid

Year of Approval approved before 1982

Publications:
TdgClinicalTrial: MORPHINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications analgesic

Drug Class Small Molecule

FDA Approval approved

Publications:

DTC: MORPHINE

Version: 02-September-2020

Alternate Names:

CHEMBL70 ChEMBL Drug ID

Drug Info:

Publications:

Cunningham CW et al., 2008, Opioids and efflux transporters. Part 2: P-glycoprotein substrate activity of 3- and 6-substituted morphine analogs., J Med Chem

Nikolaev VO et al., 2007, Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors., J Biol Chem

Vilardaga JP et al., 2008, Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling., Nat Chem Biol

NCI: MORPHINE

Version: 14-September-2017

Alternate Names:

C669 NCI drug code

Drug Info:

Publications:

El-Hage et al., 2006, CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates., J. Neuroimmunol.

Liu et al., 2005, [The effect of ribozyme specially cleaving per1 mRNA on c-fos mRNA and its expression in hippocampus of morphine addicted mice]., Space Med Med Eng (Beijing)

Xu et al., 1996, L-740,093, a new antagonist of the CCK-B receptor, potentiates the antinociceptive effect of morphine: electrophysiological and behavioural studies., Neuropeptides

PharmGKB: morphine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Darbari DS et al., 2008, UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease., Am J Hematol

Matic M et al., 2014, Effect of UGT2B7 -900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results from a pilot cohort., Pharmacogenomics

Bastami S et al., 2014, Influence of UGT2B7, OPRM1 and ABCB1 gene polymorphisms on postoperative morphine consumption., Basic Clin Pharmacol Toxicol

TTD: Morphine
- Version: 2020.06.01
Alternate Names:

D0WE3O TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL70
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
GuideToPharmacology: 135650624
- Version: 29-September-2020
Alternate Names:

Drug Info:

Publications:

Specific Action of the Ligand	Full agonist
Endogenous Drug?	False
Trial Name	ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

Trial Name	ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT
Novel drug target	Established target
Trial Name	intranasal morphine,Rylomine

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

MORPHINE Drug Record

MORPHINE chembl:CHEMBL70 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10710628

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 705020

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15977398

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14580950 10686338

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21622719

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17090705

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11054766 12595695 28006928 15927391 23686330 21398039 23302985 26902643 29474345 23773341 9259381 25155931 25185591 19514130 28745577 27027462

Sources: PharmGKB

Interaction Types & Directionality: activator (activating)

Interaction Info:

PMIDs: 20178837

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17724700 25340733 24703092 16580900 12185559 28063968 31607718

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12110611

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27027462

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10719211

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15098168

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16831471

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23835420

Sources: PharmGKB

Interaction Types & Directionality: agonist (activating)

Interaction Info: Specific Action of the Ligand Full agonist Endogenous Drug? False Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

PMIDs: 16539674 16650582 12015197 16530171 16534251 16678156 11752352

Sources: TEND TdgClinicalTrial DrugBank GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6993188

Interaction Types & Directionality:

n/a

PMIDs:
10710628

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
705020

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15977398

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14580950 10686338

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
21622719

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17090705

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11054766 12595695 28006928 15927391 23686330 21398039 23302985 26902643 29474345 23773341 9259381 25155931 25185591 19514130 28745577 27027462

Sources:
PharmGKB

Interaction Types & Directionality:

activator (activating)

PMIDs:
20178837

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
17724700 25340733 24703092 16580900 12185559 28063968 31607718

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12110611

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
27027462

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
10719211

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15098168

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16831471

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
23835420

Sources:
PharmGKB

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

PMIDs:
16539674 16650582 12015197 16530171 16534251 16678156 11752352

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
6993188

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12373743

Sources:
NCI

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name TPM-1/Morphine

Trial Name Statex

Trial Name MoxDuo

PMIDs:
16753266 29259946 7959748 9808678 17139284 17016423

Sources:
TEND PharmGKB TdgClinicalTrial DrugBank GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
8771563

Sources:
NCI

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name ALO-01, morphine sulfate and naltrexone hydrochloride,Embeda, Kadian NT

Novel drug target Established target

Trial Name intranasal morphine,Rylomine

PMIDs:
17616524 16580639 16682505 16530171 18193048 18380425 11752352 16580848

Sources:
TEND DTC TdgClinicalTrial DrugBank GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
3435201

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
32090339

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27649267